Evidence map›Paper›PMID 24982608›Full record

ArticleClinical proteomics2014

Deciphering the peptidome of urine from ovarian cancer patients and healthy controls.

Christopher R Smith, Ihor Batruch, Josep Miquel Bauça, Hari Kosanam, Julia Ridley, Marcus Q Bernardini, Felix Leung, Eleftherios P Diamandis, Vathany Kulasingam

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical proteomics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Current Challenges and Future Directions in Peptidomics.Methods in molecular biology (Clifton, N.J.) · 2024
    Article
  6. Origins, Technological Advancement, and Applications of Peptidomics.Methods in molecular biology (Clifton, N.J.) · 2024
    Article
  7. Article
  8. Multimerin-1 and cancer: a review.Bioscience reports · 2022
    Review
  9. Article
  10. LRG1: an emerging player in disease pathogenesis.Journal of biomedical science · 2022
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Christopher R SmithDepartment of Clinical Biochemistry, University Health Network, Toronto, ON, Canada ; Samuel Lunenfeld Research Institute, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada.
Ihor BatruchSamuel Lunenfeld Research Institute, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada.
Josep Miquel BauçaServei d'Anàlisis Clíniques, Hospital Universitari Son Espases, Palma de Mallorca, Spain.
Hari KosanamSamuel Lunenfeld Research Institute, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada.
Julia RidleyDepartment of Psychosocial Oncology and Palliative Care, Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada ; Division of Palliative Care, Department of Community and Palliative Medicine, University of Toronto, Toronto, ON, Canada.
Marcus Q BernardiniDepartment of Obstetrics and Gynecology, University of Toronto, Toronto, ON, Canada.
Felix LeungSamuel Lunenfeld Research Institute, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada ; Department of Laboratory Medicine and Pathobiology, University of Toronto, 200 Elizabeth Street, Room 3 EB 362A, Toronto, ON M5G 2C4, Canada.
Eleftherios P DiamandisDepartment of Clinical Biochemistry, University Health Network, Toronto, ON, Canada ; Samuel Lunenfeld Research Institute, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada ; Department of Laboratory Medicine and Pathobiology, University of Toronto, 200 Elizabeth Street, Room 3 EB 362A, Toronto, ON M5G 2C4, Canada.
Vathany KulasingamDepartment of Clinical Biochemistry, University Health Network, Toronto, ON, Canada ; Department of Laboratory Medicine and Pathobiology, University of Toronto, 200 Elizabeth Street, Room 3 EB 362A, Toronto, ON M5G 2C4, Canada.
Lunenfeld-Tanenbaum Research Institute · CAUniversity Health Network · CAUniversity of Toronto · CAHospital Universitario Son Espases · ESMount Sinai Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOvarian cancer (OvCa) is the most lethal gynecological malignancy. The emergence of high-throughput technologies, such as mass spectrometry, has allowed for a paradigm shift in the way we search for novel biomarkers. Urine-based peptidomic profiling is a novel approach that may result in the discovery of noninvasive biomarkers for diagnosing patients with OvCa. In this study, the peptidome of urine from 6 ovarian cancer patients and 6 healthy controls was deciphered.

resultsUrine samples underwent ultrafiltration and the filtrate was subjected to solid phase extraction, followed by fractionation using strong cation exchange chromatography. These fractions were analyzed using an Orbitrap mass spectrometer. Over 4600 unique endogenous urine peptides arising from 713 proteins were catalogued, representing the largest urine peptidome reported to date. Each specimen was processed in triplicate and reproducibility at the protein (69-76%) and peptide (58-63%) levels were noted. More importantly, over 3100 unique peptides were detected solely in OvCa specimens. One such promising biomarker was leucine-rich alpha-2-glycoprotein (LRG1), where multiple peptides were found in all urines from OvCa patients, but only one peptide was found in one healthy control urine sample.

conclusionsMining the urine peptidome may yield highly promising novel OvCa biomarkers.

Indexed as

BiomarkerEarly diagnosisMass spectrometryOvarian cancerUrine peptidome

Identifiers

PMID24982608
PMCPMC4065538
OpenAlexW2169098847

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.